Skip to main content
Equibles
CRVS logo

CRVS · Corvus Pharmaceuticals, Inc. · Metrics

Track CRVS — free

Use CRVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.53 -0.12 (-1.13%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$885.79M
Shares
84.12M
Volume · Oct 23 933.82K Avg daily vol (3M) 991.43K

CRVS metrics

68 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.53
Market cap
$885.79M

Price action

20 metrics
Price change (1W)
+10.6%
Price change (30D)
-10.8%
Price change (3M)
-19.4%
Price change (6M)
-34.5%
Price change (YTD)
+36.8%
Price change (1Y)
+47.1%
Trailing year
Price change (5Y)
+135.6%
52-week high
$25.52
52-week low
$6.50
Change from 52-week high
-58.7%
Change from 52-week low
+62.0%
Annualized volatility
178.9%
Annualized volatility (3M)
51.8%
Beta
-0.5
RSI (14D)
45.2
Price vs SMA 50
-15.0%
Price vs SMA 200
-26.6%
Avg volume (3M)
991,426
Relative volume
0.9
Average dollar volume
$12.34M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
84.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.9
reciprocal yield 25.4%
FCF yield
-5.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$56.96M
Net income (TTM)
−$54.13M
Trailing 12 months
Diluted EPS (TTM)
$-0.64
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.65
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.62
Operating cash flow per diluted share (TTM)
$-0.51
Free cash flow per diluted share (TTM)
$-0.52
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.52
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.82

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-24.0%
Return on assets
-22.6%
Debt / equity
0.0
Current ratio
16.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$45.23M
Quick ratio
16.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.91M
Latest balance sheet
Cash & equivalents
$18.91M
Total assets
$239.27M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$44.53M
Capital expenditures (TTM)
$698,000
R&D (TTM)
$45.53M
SG&A (TTM)
—
Stock compensation (TTM)
$8.08M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
174
13F filer change QoQ
+9
Institutional ownership
86.6%
Conviction holders (share of 13F filers)
2.9%
Crowding (high-turnover and private-fund holders)
36.9%
Private-fund adviser ownership
36.0%
Active holders' share change QoQ
-1.7%
Holder tenure
10.4
Price vs estimated holder cost
+14.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.5%

Short interest

3 metrics
Short interest
21.2%
Latest settlement · 13.3 days to cover
Days to cover
13.3d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1626971 CUSIP 221015100 13F (30d) 16 filings 16 filers Visit website Investor relations